Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
01:54 | Alpha Teknova, Inc.: Teknova to Report First Quarter 2025 Financial Results on May 8, 2025 | 1 | GlobeNewswire (USA) | ||
19.03. | Alpha Teknova, Inc.: Teknova and Pluristyx Launch Proprietary PluriFreeze Cryopreservation System to Accelerate the Development of Cell Therapies | 1 | GlobeNewswire (USA) | ||
12.03. | Teknova and Pluristyx join hands to streamline next-generation cell therapy production | 3 | Seeking Alpha | ||
12.03. | Alpha Teknova, Inc.: Teknova and Pluristyx Announce Collaboration to Streamline the Manufacture of Next-Generation Cell Therapies | 1 | GlobeNewswire (USA) | ||
ALPHA TEKNOVA Aktie jetzt für 0€ handeln | |||||
07.03. | Alpha Teknova, Inc. - 10-K, Annual Report | - | SEC Filings | ||
05.03. | Alpha Teknova stock holds as KeyBanc maintains rating | 1 | Investing.com | ||
04.03. | Alpha Teknova, Inc. Q4 Loss Narrows | 1 | RTTNews | ||
04.03. | Alpha Teknova, Inc.: Teknova Reports Fourth Quarter and Full Year 2024 Financial Results | 377 | GlobeNewswire (Europe) | Full year 2024 total revenue was $37.7 million, up 3% year-over-year and in line with guidanceFourth quarter 2024 total revenue was $9.3 million, up 18% over the same quarter prior yearCompany provides... ► Artikel lesen | |
04.03. | Alpha Teknova, Inc. - 8-K, Current Report | - | SEC Filings | ||
20.02. | Alpha Teknova, Inc.: Teknova to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025 | 1 | GlobeNewswire (USA) | ||
12.02. | Here's What Boosted Alpha Teknova (TKNO) in Q4 | 1 | Insider Monkey | ||
10.02. | Craig-Hallum initiates Alpha Teknova stock with buy rating | 1 | Investing.com | ||
08.11.24 | Alpha Teknova, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
08.11.24 | Alpha Teknova GAAP EPS of -$0.15, revenue of $9.6M | 1 | Seeking Alpha | ||
07.11.24 | Alpha Teknova, Inc. - 8-K, Current Report | - | SEC Filings | ||
09.07.24 | Alpha Teknova, Inc.: Teknova Provides Strategic Business Update and Announces Preliminary Second Quarter 2024 Results | 433 | GlobeNewswire (Europe) | Second quarter 2024 total revenue is in the range of $9.4 to $9.6 million Company reaffirms 2024 revenue guidance of $35-38 million HOLLISTER, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova... ► Artikel lesen | |
13.05.24 | Alpha Teknova, Inc.: Teknova Reports First Quarter 2024 Financial Results | 425 | GlobeNewswire (Europe) | First quarter 2024 total revenue was $9.3 million, up 2% from prior yearLaunch of Build-Tek Custom ConfiguratorCompany reaffirms 2024 revenue guidance of $35-38 million HOLLISTER, Calif., May 13,... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
TEMPUS AI | 53,50 | 0,00 % | Gemeinsam gegen Krebs: Tempus AI, AstraZeneca und Pathos AI entwickeln KI-Modell | CHICAGO, Illinois (IT-Times) - Das Diagnose-Technologie-Unternehmen Tempus AI hat heute bekannt gegeben, zusammen mit AstraZeneca und Pathos AI ein Foundation-Modell im Bereich der Onkologie zu entwickeln.... ► Artikel lesen | |
BEAM THERAPEUTICS | 20,170 | 0,00 % | Cathie Wood's ARK Sells Adaptive Biotech, Buys Beam Therapeutics Stock | ||
SPRINGWORKS THERAPEUTICS | 44,990 | 0,00 % | EQS-Adhoc: Merck KGaA: Merck bestätigt weit fortgeschrittene Gespräche mit SpringWorks Therapeutics, Inc. zu möglicher Übernahme | EQS-Ad-hoc: Merck KGaA / Schlagwort(e): Firmenübernahme
Merck KGaA: Merck bestätigt weit fortgeschrittene Gespräche mit SpringWorks Therapeutics, Inc. zu möglicher Übernahme
24.04.2025 /... ► Artikel lesen | |
ARCELLX | 63,97 | 0,00 % | Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights | REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 36,680 | 0,00 % | Summit Therapeutics: Überzeugende Daten - BioNTech gibt ebenfalls mächtig Gas | Die Biotech-Gesellschaft Summit Therapeutics, mit einem Börsenwert von gut 20 Milliarden Dollar kein kleines Unternehmen mehr, kann am Mittwoch erneut über vielversprechende Daten zum großen Hoffnungsträger... ► Artikel lesen | |
QIAGEN | 37,525 | -0,23 % | UBS stuft QIAGEN NV auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Qiagen bei einem Kursziel von 48 US-Dollar auf "Neutral" belassen. Die Ziele seien bestätigt worden, nähere Details seien... ► Artikel lesen | |
BIONTECH | 103,40 | +1,17 % | BioNTech Aktie: Leichte Erholung im Fokus | BioNTech zeigt technische Erholungssignale trotz schwieriger Bewertung. Analysten halten an Kaufempfehlungen fest - wohin steuert die Aktie? Die BioNTech-Aktie zeigt nach turbulenten Wochen erste Anzeichen... ► Artikel lesen | |
EVOTEC | 7,278 | -0,90 % | Deutsche Telekom, Evotec, Meta Platforms, Rheinmetall, Siemens Energy, Talanx - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
EDGEWISE THERAPEUTICS | 15,400 | 0,00 % | Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) | - Phase 2 trial of EDG-7500 demonstrated rapid and clinically meaningful reductions in LVOT gradients in participants with obstructive HCM -- Four-week treatment with EDG-7500 demonstrated... ► Artikel lesen | |
VERA THERAPEUTICS | 23,470 | 0,00 % | Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on April 3, 2025, the Compensation Committee granted inducement awards consisting of... ► Artikel lesen | |
VIR BIOTECHNOLOGY | 6,290 | 0,00 % | Vir Biotechnology, Inc.: Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025 | Phase 2 SOLSTICE subgroup analysis data in chronic hepatitis delta selected for poster presentation, and to be highlighted during EASL poster tour 24 Week post-treatment follow-up data... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,750 | 0,00 % | Recursion Pharmaceuticals: Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025 | ||
ADMA BIOLOGICS | 22,340 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | FY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase FY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation Allowance Tax Benefit FY 2024 Adjusted EBITDA(1)... ► Artikel lesen | |
RELAY THERAPEUTICS | 3,190 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival | New interim data show 11.4-month median PFS in 2L patients with PI3Ka-mutated, HR+/HER2- metastatic breast cancer at RP2D 39% confirmed ORR across all patients & 67% in patients with kinase mutations... ► Artikel lesen | |
OLEMA PHARMACEUTICALS | 5,100 | 0,00 % | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development... ► Artikel lesen |